ERYP logo

ERYTECH Pharma SA (ERYP) Stock

Profile

Full Name:

PHAXIAM Therapeutics S.A.

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

05 July 2016

Indexes:

Not included

Description:

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Sept 11, 2023

Recent annual earnings:

Mar 22, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

05 Dec '17 Cowen & Co.
Outperform

Screeners with ERYP included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
ERYP
Seeking Alpha13 May 2023

Erytech Pharma SA (NASDAQ:ERYP ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Gil Beyen - CEO Thibaut du Fayet - CEO, Pherecydes Pharma Didier Hoch - Chairman, Pherecydes Pharma Conference Call Participants Jacob Mekhael - Kempen & Co. Operator Thank you for standing by, and welcome to the conference call on the proposed merger between ERYTECH Pharma and Pherecydes Pharma. [Operator Instructions].

Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
ERYP
InvestorPlace09 May 2023

Erytech Pharma (NASDAQ: ERYP ) stock is on the rise Tuesday after the company provided investors with a business update for Q1! First up is the company's planned merger with Pherecydes.

FAQ

  • What is the primary business of ERYTECH Pharma SA?
  • What is the ticker symbol for ERYTECH Pharma SA?
  • Does ERYTECH Pharma SA pay dividends?
  • What sector is ERYTECH Pharma SA in?
  • What industry is ERYTECH Pharma SA in?
  • What country is ERYTECH Pharma SA based in?
  • When did ERYTECH Pharma SA go public?
  • Is ERYTECH Pharma SA in the S&P 500?
  • Is ERYTECH Pharma SA in the NASDAQ 100?
  • Is ERYTECH Pharma SA in the Dow Jones?
  • When was ERYTECH Pharma SA's last earnings report?
  • When does ERYTECH Pharma SA report earnings?

What is the primary business of ERYTECH Pharma SA?

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

What is the ticker symbol for ERYTECH Pharma SA?

The ticker symbol for ERYTECH Pharma SA is NASDAQ:ERYP

Does ERYTECH Pharma SA pay dividends?

No, ERYTECH Pharma SA does not pay dividends

What sector is ERYTECH Pharma SA in?

ERYTECH Pharma SA is in the Healthcare sector

What industry is ERYTECH Pharma SA in?

ERYTECH Pharma SA is in the Biotechnology industry

What country is ERYTECH Pharma SA based in?

ERYTECH Pharma SA is headquartered in France

When did ERYTECH Pharma SA go public?

ERYTECH Pharma SA's initial public offering (IPO) was on 05 July 2016

Is ERYTECH Pharma SA in the S&P 500?

No, ERYTECH Pharma SA is not included in the S&P 500 index

Is ERYTECH Pharma SA in the NASDAQ 100?

No, ERYTECH Pharma SA is not included in the NASDAQ 100 index

Is ERYTECH Pharma SA in the Dow Jones?

No, ERYTECH Pharma SA is not included in the Dow Jones index

When was ERYTECH Pharma SA's last earnings report?

ERYTECH Pharma SA's most recent earnings report was on 11 September 2023

When does ERYTECH Pharma SA report earnings?

The date for ERYTECH Pharma SA's next earnings report has not been announced yet